The number of subjects in the control and CRC groups to compare the diagnostic value between IGFBP-1 and the classic clinical tumor markers (CEA and CA19-9) was not balanced, which may reduce statistical power. This evidence concerns the gene CEACAM5 and colorectal carcinoma.